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Comparative impact assessment of child pneumonia 
interventions
Louis Niessen,a Anne ten Hove,b Henk Hilderink,c Martin Weber,d Kim Mulholland e & Majid Ezzati f
Objective To compare the cost-effectiveness of interventions to reduce pneumonia mortality through risk reduction, immunization and 
case management.
Methods Country-specific pneumonia burden estimates and intervention costs from WHO were used to review estimates of pneumonia 
risk in children under 5 years of age and the efficacy of interventions (case management, pneumonia-related vaccines, improved 
nutrition and reduced indoor air pollution from household solid fuels). We calculated health benefits (disability-adjusted life years, 
DALYs, averted) and intervention costs over a period of 10 years for 40 countries, accounting for 90% of pneumonia child deaths.
Findings Solid fuel use contributes 30% (90% confidence interval: 18–44) to the burden of childhood pneumonia. Efficacious 
community-based treatment, promotion of exclusive breastfeeding, zinc supplementation and Haemophilus influenzae type b (Hib) 
and Streptococcus pneumoniae immunization through existing programmes showed cost-effectiveness ratios of 10–60 International 
dollars (I$) per DALY in low-income countries and less than I$ 120 per DALY in middle-income countries. Low-emission biomass 
stoves and cleaner fuels may be cost-effective in low-income regions. Facility-based treatment is potentially cost-effective, with ratios 
of I$ 60–120 per DALY. The cost-effectiveness of community case management depends on home visit cost.
Conclusion Vaccines against Hib and S. pneumoniae, efficacious case management, breastfeeding promotion and zinc supplementation 
are cost-effective in reducing pneumonia mortality. Environmental and nutritional interventions reduce pneumonia and provide other 
benefits. These strategies combined may reduce total child mortality by 17%.
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Introduction
Progress in reducing mortality from pneumonia in children 
under 5 years of age has been relatively slow in many parts of 
the developing world, where about 155 million clinical pneu-
monia episodes and 2 million deaths occur annually.1,2 Risk 
factors for pneumonia include stunting and underweight,1,3,4 
suboptimal breastfeeding,5,6 lack of immunization7,8 and in-
door air pollution from household use of solid fuels.9–12 There 
is evidence that effective and appropriate management of 
clinical cases is possible13,14 at health-care facilities15 and in the 
community,16 but this level of management is often lacking.
Efforts to control pneumonia are needed to meet Millen-
nium Development Goal 4 (MDG 4), to reduce child mortal-
ity in the world by two-thirds by 2015.17 Often, a package 
of priority interventions is developed to address MDG 
targets and reduce child mortality.4,6,18–20 Cost-effectiveness 
analysis has become vital in deciding what interventions to 
implement and scale up.21 Single-candidate interventions to 
reduce pneumonia have been evaluated in general economic 
terms,6,11,18,22–24 but no comprehensive analysis has focused 
on pneumonia control.
Different interventions can affect incidence or case fatal-
ity, with differences noted across age groups. Population risk 
interventions can target specific subpopulations, while immu-
nization is intended for all infants. Preventive interventions 
of this kind may reduce the incidence of pneumonia, whereas 
case management influences case fatality after falling ill. Both 
types of interventions can reduce pneumonia mortality.
The aim of this study was to compare the impact of 
eight preventive and curative interventions at the population 
level6,25–27 and to identify the intervention mixes that generate 
the highest possible level of child health at the lowest cost.
Methods
To estimate the population health effects and total costs of 
pneumonia interventions from a health-care perspective, we 
applied demographic life tables for the 40 countries with the 
highest mortality (list available at: http://oldwww.bmg.eur.nl/
personal/niessen/Webtable%20Countries%20by%20Region.
doc The tables were used to estimate the health effect of risk 
factors, as well as the reductions in incidence and case fatality 
in population cohorts, simultaneously and consistently.6,25–27 
Detailed descriptions of concepts, methods, background 
papers, regional studies and data are available at: WHO-
CHOICE (CHOosing Interventions that are Cost Effective) 
at: www.who.int/choice/en. Box 1 provides an overview of 
the approach.
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We considered the epidemiologi-
cal characteristics and level of health 
care of each of the 40 countries, as well 
as the coverage levels of the expanded 
programme on immunization (EPI) 
and of facility-based case management. 
Due to the large uncertainties involved 
in the epidemiologic, effectiveness and 
cost estimates, we included a high and a 
low cost-effectiveness scenario for each 
mix of interventions.
Each country’s life table provides 
summary estimates of how pneumonia 
affects mortality and morbidity, ex-
pressed in terms of disability-adjusted 
life years (DALYs) lost. The tables also 
provide estimates of the effect and cost 
of mixed health interventions, in United 
States dollars (US$) for the year 2000, 
with a 3% discount rate according to 
health economics guidelines. We com-
bined estimated health gains and costs 
per intervention to identify the sets of 
health interventions that maximized 
child health at different budget levels 
by providing the greatest health yield 
per dollar spent. The life tables were 
implemented in C++ (a general pro-
gramming language) using M language 
(a language for working with data and 
building domain models). The script 
with M-equations is available at: http://
oldwww.bmg.eur.nl/persona/niessen/
GAPP_LOW.MPdf.pdf
Epidemiologic and demographic 
data
The life tables used in the model were 
based on the recently published WHO 
country data, which draw on reviews of 
incidence and mortality for childhood 
and neonatal pneumonia. Incidence 
estimates were taken from the epide-
miological review.1 Consistent applied 
case-fatality rates were calculated by 
dividing annual incidence figures by 
annual mortality rates from the global 
burden of disease data set.2,7
Risk factor prevalence data were 
derived from the WHO Statistical 
Information System (WHOSIS), avail-
able at: http://www.who.int/whosis/en/
index.html They included nonexclusive 
breastfeeding, undernutrition (defined 
as underweight for age, z < −2), measles 
immunization coverage and exposure to 
indoor air pollution in the population 
under 5 years of age. Relative risks of 
indoor air pollution by type of biomass 
fuel for pneumonia incidence were de-
Box 1.  Stepwise description of impact assessment for comparatively analysing the 
costs and effects of interventions6,25,26
1. Construct epidemiologic disease model. Give a population-based description; establish how 
parameters of the disease model interact (i.e. relative risks, incidence, case-fatality ratio, 
neonatal and mortality rates, by age group and sex);
2. Review national data for year of study. Include population structure and absolute figures, 
births, pneumonia epidemiologic rates and intervention coverage;
3. Construct baseline epidemiological parameters. Reflect current population figures and 
epidemiologic rates, a situation of limited health care and the future United Nations 
demographic scenario;
4. Estimate effectiveness. Repeat analysis under Step 3 with changes to one or more key 
epidemiological parameters (incidence or case–fatality rate) as a result of intervention 
effectiveness; compute the total number of healthy life years gained (or of DALYs averted).
5. Estimate costs. Establish coverage and contact rates; apply unit costs and add programme 
costs by intervention mix.
6. Generate a cost and effectiveness league table. Estimate the total costs and health benefits 
(DALYs averted) of single interventions and intervention mixes and establish a ranking table 
based on the cost-effectiveness ratio.
DALY, disability-adjusted life year.
rived from the Global Action Plan for 
Pneumonia (GAPP).9,10,28 Other rela-
tive risks for pneumonia incidence were 
obtained from the same review.1
National statistics on neonatal, in-
fant and child mortality for 2005 were 
obtained from the online database of 
the Institute for Health Metrics and 
Evaluation.7 The fractions of neonatal 
mortality attributable to pneumonia 
and sepsis were obtained from the The 
Lancet nutrition series.20 Case-fatality 
ratios for children are specified by 
three age groups: neonatal period until 
1 month of age, remainder of the first 
year (2−12 months of age) and 1–5 
years.
The disability weight used to com-
pute pneumonia morbidity for a disease 
episode lasting 2 weeks was 0.279.29 
DALYs were calculated by applying 
the region-specific disability weights 
for the general population by age and 
sex.30 Country-level demographic data 
on population structure, birth rates and 
general mortality rates were obtained 
from official 2005 estimates by the 





In all scenarios we assumed a pro-
gramme effectiveness time horizon of 
10 years for all interventions, starting 
in 2005. After that, the new popula-
tion cohorts resumed pre-intervention 
status, in line with the standardized 
cost-effectiveness approach of WHO-
CHOICE project.6 The calculations 
included the extra life-years lived by 
additional surviving children beyond 
the 10-year period, as well as the 
pneumonia incidence reduction from 
immunization until the last immunized 
age group reaches the age of 5 years (in 
2020). We estimated total health effects 
over a period of 100 years to include 
all life-years gained beyond the 10-year 
time horizon, among all survivors. We 
calculated intervention costs in Interna-
tional dollars (I$) to allow comparisons.
Table 1 shows the selected inter-
ventions and related input data for vari-
ous scenarios. The subsections below 
describe the scenario assumptions by 
intervention category.
Reduction of indoor air pollution
The 90% confidence interval (CI) of 
the relative risk (RR) of pneumonia 
due to exposure to indoor air pollution 
was estimated to be 1.42 to 2.53.28 Two 
interventions for indoor air pollution 
were selected.9,28 The first was a switch 
at the household level to cleaner gaseous 
or liquid fuels (liquefied petroleum gas, 
kerosene or ethanol); the second was 
better combustion ventilation through 
high-quality and well-maintained bio-
mass stoves. The health effect of inter-
vening against this risk factor derives 
primarily from observational studies 
(including one unpublished random-
ized study of high-quality stoves). The 
GAPP reviews assumed that introducing 
cleaner fuel reduces pneumonia risk.9,28 
Based on this assumption, changing to 
full-scale cleaner household fuel could 
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Table 1. Input data for pneumonia intervention effectiveness, estimated health care costs and literature sources, 2005
Code Intervention Effectivenessa 
low‑high scenario range




E1 Liquid fuel stoves RR-based exposure reduction [ formula: 
(1 – (1 ¤ RR l) b ) – (1 – (1 ¤ RRh) c ) ]
Incidence 9 I$ 8.57–14.47 in AMR Dd per 
household member, per year
23
E2 Improved solid fuel 
stoves
RR-based exposure reduction 75% 
in specific settings
Incidence 9 I$ 4.82–7.59 in AMR Dd per 





15–23% reduction in infants Incidence 3,6 I$ per child WHO 
data sete





23–35% reduction Incidence 8 I$ 19–64 per immunized child 24
I2 Haemophilus 
influenzae type B




C1 Community-based 34–50% (90% CI: 22–57) for 
neonatal pneumonia
Case fatality 13,16,31 1–2 visits of I$ 2.13–9.40 per 
incident case
14
C2 Facility-based 29–45% (90% CI: 20–49) Case fatality 32 I$ per child WHO 
data sete
AMR, WHO Region of the Americas; CI, confidence interval; I$, International dollar; RR, relative risk (values from review).28
a  Age-specific reductions in exposure among all age groups under 5 years, unless otherwise indicated.
b  RR
l
 is the relative risk of pneumonia under low exposure (1.42 in this study).
c  RR
h
 is the relative risk of pneumonia under high exposure (2.53 in this study).
d  High-tech and low-tech liquid fuel stoves were considered, as well as an improved stove for solid fuels.23 For the latter, we assumed a 2-year (high-cost scenario) 
and a 4-year (low-cost scenario) average lifetime. Cost data are WHO-region specific.
e  WHO-CHOICE (CHOosing Interventions that are Cost Effective) dataset for child survival interventions (http://www.who.int/choice/en), November 2007. Data are 
WHO-region specific.
lower pneumonia incidence by 50% 
(the attributable burden for indoor 
air pollution). However, high-quality, 
well-maintained stoves are not expected 
to prevent all exposure to indoor air 
pollution. In an earlier review and cost-
effectiveness study, a 75% reduction in 
exposure was assumed in a scenario of 
full coverage with good stoves.11 Given 
the high and low RRs linked to in-
door air pollution under this scenario 
(equations in Table 1), the pneumonia 
incidence reduction would be 22.2% 
to 45.8%.28 The cost methodology 
and actual cost estimates are based on 
WHO reports11,23 with a two- or four-
year stove lifetime.
Nutritional interventions
Selected nutritional interventions to re-
duce pneumonia were exclusive breast-
feeding promotion up to 6 months of 
age6,18 and food supplementation with 
zinc.3,33 Region-specific cost estimates 
were based on those from the WHO-
CHOICE programme.
Immunizations
The scenarios included two vaccines 
as potential interventions to reduce 
pneumonia risk. The measles vaccine 
was not included, since its already high 
coverage in most of the 40 countries 
studied would have made its effect 
on pneumonia mortality difficult to 
quantify. The population effectiveness 
of immunization depends on the level 
of protection against the bacteria (Hib 
and pneumococcus), but even more 
on the actual attributable contribution 
of these bacteria to the pneumonia 
burden. Hib and pneumococcus may 
account for more than half of pneumo-
nia mortality in children.17 The relative 
importance of these bacteria as causes 
of pneumonia in different settings is 
unknown, but the similarity of the trial 
results suggests that major differences 
between populations do not exist. The 
effectiveness range given by the high 
and low country scenarios takes into 
account the variety of agents (Table 1). 
The joint effect of the two vaccination 
programmes targeting two different 
microorganisms was assumed to be ad-
ditive. The cost estimates were based on 
earlier economic evaluations.22,24 Imple-
mentation was assumed to occur within 
existing immunization programmes and 
infrastructure.
Pneumonia case management
Two delivery strategies were chosen to 
treat children with pneumonia: a facil-
ity-based approach,15 and a community-
level approach in which children were 
diagnosed and treated by community 
health workers.16 The estimated reduc-
tion of pneumonia mortality through 
pneumonia case management was 
based on two reviews.13,16 These reported 
an efficacious (i.e. under ideal circum-
stances) reduction of 42% (90% CI: 
22–57) in neonatal pneumonia mor-
tality and of 36% (90% CI: 20–49) in 
child pneumonia mortality, confirmed 
by a review of management by com-
munity health workers.31 We subtracted 
these expected reductions from the 
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Table 2. Population using solid fuels, and PAR for pneumonia mortality among children < 5 years of age, by WHO subregions, 2005
WHO 
subregiona








RRc = 2.53)No. %
AFR D 304 199 839 211 063 296 69 36 23 51
AFR E 338 409 271 273 010 077 81 39 25 55
AMR A 325 897 888 18 074 771 6 4 2 8
AMR B 435 563 238 57 197 830 13 10 5 17
AMR D 70 637 557 28 599 404 40 24 15 38
EMR B 137 098 168 11 394 365 8 6 3 11
EMR D 346 537 669 175 005 075 51 29 17 44
EUR A 413 765 659 21 062 657 5 4 2 7
EUR B 218 138 441 55 160 415 25 17 10 28
EUR C 242 471 330 19 684 368 8 6 3 11
SEAR B 290 459 728 208 138 629 72 36 23 52
SEAR D 1 246 955 684 951 016 609 76 38 24 54
WPR A 154 258 746 7 898 007 5 4 2 7
WPR B 1 532 885 216 1 137 968 143 74 37 24 53
Residual 11 915 069 2 770 500 23 16 9 26
World 6 069 193 503 3 178 044 147 52 30 18 44
CI, confidence interval; PAR, population-attributable risk; RR, relative risk.
a  AFR, WHO African Region; AMR, WHO Region of the Americas; EMR, WHO Eastern Mediterranean Region; EUR, WHO European Region; SEAR, WHO South-East Asia 
Region; WPR, WHO Western Pacific Region. WHO regions are subdivided based on child and adult mortality: A, very low child and very low adult mortality; B, low 
child and low adult mortality; C, low child and high adult mortality; D, high child and high adult mortality; E, high child and very high adult mortality. A list of countries 
in WHO subregions is available at: http://www.who.int/choice/demography/regions
b  Based on [P × (RR – 1)] / [(P × (RR – 1) + 1] where P is risk prevalence and RR is the relative risk related to the exposure to solid fuel use.2,25 The calculations 
include 90% CIs for the RR of pneumonia (based on the aggregate of 40 high-burden countries).
c  The RR value range is based on the systematic review.28
Table 3.  High and low estimates of child mortality reduction for two pneumonia 
intervention packages for 40 countries clustered by WHO subregion
WHO 
subregiona
C1, N1, N2, I1, I2 package E1, C1, N1+2, I1+2 package
Highb Lowb Highb Lowb
AFR D 10.7 7.8 12.9 9.5
AFR E 14.7 10.8 17.3 13.2
AMR B 8.6 6.3 9.8 7.3
AMR D 8.6 6.3 9.8 7.3
EMR D 14.4 10.5 17.0 12.7
SEAR B 7.1 5.2 8.2 6.2
SEAR D 8.5 6.1 10.3 7.5
WPR B 9.1 6.7 10.3 7.9
C1, case management community-based; E1, use of cleaner liquid fuels; I1, pneumococcal vaccine; 
I2, Haemophilus influenza type B vaccine; N1, breastfeeding promotion; N2, zinc supplementation.
a  AFR, WHO African Region; AMR, WHO Region of the Americas; EMR, WHO Eastern Mediterranean Region; 
SEAR, WHO South-East Asia Region; WPR, WHO Western Pacific Region. WHO regions are subdivided 
based on child and adult mortality: A, very low child and very low adult mortality; B, low child and low 
adult mortality; C, low child and high adult mortality; D, high child and high adult mortality; E, high child 
and very high adult mortality. A list of countries in WHO subregions is available at: http://www.who.int/
choice/demography/regions
b  The low and high figures are based on the low and high scenario input values in Table 1.
country-specific, age-specific case fatality 
rates, while we included the uncertainty 
range based on the CI. In severe cases 
(8.6% of all incident cases), we assumed 
a case fatality reduction of 51%.32 The 
cost data of case-management strategies 
at the facility level are from the WHO-
CHOICE programme and updates by 
WHO’s Child and Adolescent Health 
Department.21,32 The community-based 
cost estimates are from the Disease Con-
trol Priorities in Developing Countries 
(DCP2) project.14 We varied the number 
of budgeted visits by a village agent to 
children treated for pneumonia by one 
(low-cost scenario) to two times (high-
cost scenario).14,31
Results
Table 2 shows the regional aggregate 
results on the effect of using solid fuels 
on pneumonia mortality in children. 
Table 3 shows the potential impact 
of pneumonia interventions on total 
mortality among children under 5, 
and Table 4 lists the cost-effectiveness 
ratios. In each table, all eight interven-
tion options are grouped into the four 
intervention areas described above 
(indoor air pollution, undernutrition, 
immunization and case management). 
In the country profiles, further expan-
sion of pneumonia programmes is con-
sidered, alongside existing vaccination 
programmes and curative services.
The attributable pneumonia bur-
den due to indoor air pollution by 
WHO region was based on the country-
specific exposure estimates from the 
WHOSIS database. The two countries 
with the largest populations – China 
and India – showed a high level (> 70%) 
of solid fuel use. The attributable bur-
den for indoor air pollution in world 
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regions varied from 10% to 38%, with 
a limited uncertainty range. The con-
tribution of indoor air pollution to the 
global burden of childhood pneumonia 
is large (30%; CI: 18–44). Table 3 pro-
vides the aggregated results by WHO 
region of health gains for two inter-
vention packages in the high-burden 
countries.
Table 5, which illustrates the possi-
bilities for country-level policy-making, 
presents two country profiles with 
combinations of eight intervention 
scenarios. Both single (Table 4) and 
combined interventions (Table 5) show 
low-cost outcomes between I$ 10 and 
I$ 60 per DALY averted for interven-
tions in the WHO Africa D and E 
subregions, and in the WHO Eastern 
Mediterranean D subregion. In other 
regions, effective options were immu-
nization, nutritional interventions and 
community-based case management. 
A listing of WHO epidemiological 
subregions is available at: http://www.
who.int/choice/demography/regions 
Many mixes of interventions fell in the 
cost range of I$ 60 to I$ 120 per DALY 
averted; others were less cost-effective 
in light of the general country income 
level. In some poorer regions, the two 
indoor air pollution interventions 
showed the same cost-effective levels 
as other interventions. In general, the 
indoor air pollution interventions ap-
pear to be less cost-effective than other 
interventions for reducing pneumonia 
mortality. The maximum potential 
reduction in child mortality, given 
Table 4.  High and low cost‑effectiveness estimates (I$ per DALY averted) of single interventions to reduce pneumonia mortality, for 




E1 E2 N1 N2 I1 I2 C1 C2
Lowb Highb Lowb Highb Lowb Highb Lowb Highb Lowb Highb Lowb Highb Lowb Highb Highb Highb
SEAR B 1567 8918 930 3312 177 242 66 105 238 1292 159 407 90 274 780 1011
SEAR D 808 2149 448 1647 67 90 25 40 109 593 115 293 69 210 277 357
WPR B 3200 17 823 1382 5612 299 407 86 137 266 1447 238 610 112 343 678 879
AFR D 107 356 72 243 49 66 12 19 44 241 27 69 21 65 62 81
AFR E 232 780 139 498 35 48 12 19 45 244 46 120 35 107 64 83
EMR D 135 837 86 296 47 63 16 26 50 273 35 89 66 203 71 92
AMR D 467 1572 343 1097 218 295 18 28 223 1207 96 245 108 330 492 635
AMR B 1226 3936 1420 3812 261 356 17 27 243 1324 130 335 56 172 489 637
C1, case management community-based; C2, case management facility-based; DALY, disability-adjusted life year; E1, use of cleaner liquid fuels; E2, solid fuel stoves; 
I1, pneumococcal vaccine; I2, Haemophilus influenza type B vaccine; I$, International dollar; N1, breast feeding promotion; N2, zinc supplementation.
a  AFR, WHO African Region; AMR, WHO Region of the Americas; EMR, WHO Eastern Mediterranean Region; SEAR, WHO South-East Asia Region; WPR, WHO Western 
Pacific Region. WHO regions are subdivided based on child and adult mortality: A, very low child and very low adult mortality; B, low child and low adult mortality; C, 
low child and high adult mortality; D, high child and high adult mortality; E, high child and very high adult mortality. A list of countries in WHO subregions is available 
at: http://www.who.int/choice/demography/regions
b  The low and high cost-effectiveness figures are based on the low and high scenario input values in Table 1.
existing infrastructures and including 
indoor air pollution interventions, ap-
pears to be about 13–17%. Thus, most 
of the child pneumonia mortality could 
be avoided if all interventions were 
implemented.
Discussion
Population-based preventive measures 
and expanding community-based case 
management appear to be the most ef-
fective options for reducing pneumonia 
mortality. Adding these measures to 
existing facility-based case management 
would increase the efficiency of health 
system as a whole. When outreach ex-
pansion is limited and infrastructure is 
lacking, immunization is costly. Where 
measles vaccination coverage is already 
high, both types of pneumonia vaccine 
are attractive options. The estimates on 
immunization depend strongly on the 
price per dose. Expanded case manage-
ment, combined with expanded use of 
new vaccines, would increase system 
efficiency further. Adding new vaccines 
and expanding immunization coverage, 
nutritional interventions and commu-
nity case management lead to relatively 
cost-effective pneumonia packages, as 
compared with facility-based manage-
ment alone, because the latter was more 
costly in all scenarios.
Additionally, we found that health 
risk reduction through nutritional 
and immunization intervention pro-
grammes increases the cost-effectiveness 
of programmes for case management 
of childhood illnesses. The region and 
country league tables present the ad-
ditional cost-effective options of ex-
panded community case management 
and improved neonatal management.
The cost-effectiveness results 
showed the efficiency of implement-
ing interventions alongside an existing 
health care structure, in comparison 
with a baseline situation. Presenting 
the results in this way provides policy-
makers with a general impression of 
the impact of an intervention; it also 
makes it possible to compare the ef-
ficiency of existing and new packages 
and possible ways to improve the al-
location of funds. For example, in a 
country such as Guatemala, the most 
attractive additional options would 
be zinc supplementation combined 
with community case management. 
If these interventions were introduced 
simultaneously with the available envi-
ronmental interventions, the additional 
cost of the package per DALY would 
increase. When environmental inter-
ventions are introduced wherever other 
interventions are already in place, the 
extra health benefits are limited and the 
additional cost per DALY (i.e. marginal 
cost-effectiveness) can be high. For 
example, in a country such as Nigeria, 
which has some infrastructure but no 
proven options to reduce indoor air 
pollution, including up-scaling com-
munity case management, along with 
preventive programmes, would increase 
the cost-effectiveness of implementing 
a pneumonia control package.
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Table 5.  Impact of pneumonia interventions: population costs and health effects of intervention mixes, ranked by cost‑
effectiveness ratio
Scenario Cost Impact Cost‑effectiveness
(I$) (DALYs averted) (I$ per DALY averted)
Lowa Higha Lowa Higha Low High
Guatemala
N2 3 388 548 3 388 755 94 708 168 753 20 36
C1 + N2 14 456 120 22 847 770 153 759 248 160 58 149
N2 + I2 22 947 950 35 885 920 197 545 310 204 74 182
C1 + N2 + I2 32 557 260 51 380 010 247 505 370 709 88 208
I2 19 556 400 32 489 570 117 737 181 722 108 276
C1 + I2 30 645 650 52 833 210 175 482 261 407 117 301
C1 12 771 920 25 549 410 68 752 105 082 122 372
N2 + I1 + I2 69 744 980 202 430 400 304 660 455 961 153 664
C1 + N2 + I1 + I2 77 836 540 213 846 400 345 132 496 946 157 620
C1 + I1 + I2 75 686 320 214 000 500 286 650 422 480 179 747
I1 + I2 66 348 560 199 012 700 239 878 368 496 180 830
N1 + N2 + I1 + I2 92 885 300 225 585 800 339 382 489 399 190 665
C1 + N1 + N2 + I1 + I2 100 765 800 236 592 300 376 289 525 116 192 629
N1 23 128 920 23 129 580 61 849 94 573 245 374
I1 46 777 990 166 457 900 122 548 187 061 250 1 358
E2 + N1 + N2 102 294 300 145 676 800 223 486 369 041 277 652
E2 + N1 + N2 + I1 + I2 168 673 800 344 773 400 391 775 557 602 302 880
E1 + N2 + I1 + I2 207 344 100 429 838 300 380 875 559 431 371 1 129
E2 75 765 250 119 135 400 96 467 196 759 385 1 235
C1 + N1 + N2 + E1 + I1 + I2 236 928 300 459 878 300 439 383 602 671 393 1 047
I1 + C2 105 490 400 225 193 400 183 402 266 837 395 1 228
E1 + N1 + N2 + I1 + I2 230 488 000 452 992 500 409 236 580 330 397 1 107
E1 137 565 200 227 326 900 128 460 262 222 525 1 770
C2 58 702 570 58 704 310 72 978 106 185 553 804
Nigeria
N2 128 164 700 128 202 800 3 762 062 6 731 571 19 34
C1 168 511 300 337 498 200 5 526 855 8 480 821 20 61
C1 + N2 274 758 000 387 071 600 8 583 929 13 260 480 21 45
C1 + I2 258 060 800 471 722 200 7 368 852 11 046 040 23 64
C1 + N2 + I2 365 650 800 528 628 400 10 237 650 15 369 100 24 52
N2 + I2 227 851 200 293 837 000 5 713 960 9 466 567 24 51
I2 99 643 700 165 537 400 2 173 602 3 366 076 30 76
C1 + N2 + I1 + I2 608 643 400 1 401 358 000 11 960 940 17 543 130 35 117
C1 + I1 + I2 499 627 700 1 336 704 000 9 288 789 13 691 530 36 144
N2 + I1 + I2 479 963 200 1 191 108 000 7 748 521 12 287 710 39 154
C1 + N1 + N2 + I1 + I2 831 553 600 1 618 765 000 12 606 920 18 236 400 46 128
I1 + I2 351 680 200 1 062 450 000 4 450 029 6 849 750 51 239
N1 + N2 + I1 + I2 706 739 500 1 418 207 000 8 546 800 13 268 470 53 166
E2 + N1 + N2 1 019 693 000 1 444 036 000 8 300 044 14 377 170 71 174
I1 251 974 300 896 624 000 2 263 079 3 465 493 73 396
E2 + N1 + N2 + I1 + I2 1 371 835 000 2 507 878 000 11 689 880 18 402 300 75 215
E2 664 495 100 1 088 280 000 4 275 433 8 763 258 76 255
E1 + N2 + I1 + I2 1 800 313 000 3 322 043 000 12 097 260 19 531 300 92 275
C1 + N1 + N2 + E1 + I1 + I2 2 127 876 000 3 669 423 000 16 001 450 23 081 510 92 229
C2 804 987 900 805 210 800 5 870 092 8 570 428 94 137
I1 + C2 1 057 172 000 1 702 514 000 7 765 486 11 202 330 94 219
E1 + N1 + N2 + I1 + I2 2 027 254 000 3 549 299 000 12 738 820 20 116 860 101 279
E1 1 319 492 000 2 128 944 000 5 706 202 11 697 470 113 373
N1 226 542 300 226 555 500 1 067 216 1 642 060 138 212
C1, case management community-based; C2, case management facility-based; DALY, disability-adjusted life year; E1, use of cleaner liquid fuels; E2, use of solid fuel 
stoves; I1, pneumococcal vaccine; I2, Haemophilus influenza type B vaccine; I$, International dollar; N1, breastfeeding promotion; N2, zinc supplementation.
a  The low and high cost-effectiveness figures are based on the low and high scenario input values in Table 1.
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Data are limited in almost all 
countries. Detailed data on pneumonia 
deaths are lacking, and community-
based data on clinical episodes are 
sparse.1 Research is needed to better 
diagnose pneumonia and identify it 
as the cause of death. Our results are 
therefore difficult to validate beyond 
the recent reviews presented, whose 
quality determines the results of the 
economic impact evaluation. We were 
unable to distinguish between studies 
that reported intervention efficacy and 
those that reported community effec-
tiveness. We attempted to consider this 
issue and other sources of uncertainty 
in our high and low effectiveness and 
cost scenarios; however, better data on 
community effectiveness and associated 
costs are needed. New preventive inter-
ventions may lead to net cost savings 
by preventing costly disease. However, 
we did not take into account potential 
savings due to cost offsets, lower use 
of health services and averted loss of 
workdays due to fewer illness episodes. 
Our results are thus conservative.
A point of debate is the cost of 
investing in cleaner fuels, whose cost 
per DALY averted is higher than that 
of other options. The results are not 
directly comparable, however, because 
the cost of cleaner fuels is offset by 
other societal benefits, such as time 
saved looking for firewood or other 
biomass fuels. If only the additional 
implementation efforts in an already 
existing health sector setting are con-
sidered and the extra costs of clean fuels 
are ignored, the cost-effectiveness ratio 
is lower. Uncertainty also surrounds the 
effectiveness and cost of community 
case management programmes. These 
are likely to be directly correlated with 
the quality improvements and the ad-
ditional cost per village of visits by a 
village agent. These variables make it 
difficult to draw definite conclusions 
from the economic evaluation of these 
interventions. Still, our studies have 
identified three potentially valuable 
interventions to improve child survival: 
nutritional interventions, immuniza-
tion and low-cost, effective case man-
agement. Innovative use of vaccines, 
focusing on the highest at-risk groups, 
could amplify the impact.
National priorities
Donors and national agencies involved 
in child survival programmes need to 
select those that maximize child health 
after considering existing mortality lev-
els, infrastructure and funds available.34 
The present study, focused on children, 
offers policy-makers a range of potential 
pneumonia interventions and estimates 
of the money they require.35
Internationally, there is agreement 
on using disease-burden estimates and 
data on the cost-effectiveness of inter-
ventions to select priority areas. New 
insights should be applied in real-life 
country settings to find local solutions 
and implement appropriate options. 
Country programme managers need 
more specific information on the ef-
fects and costs of child programmes 
so they can weigh them against other 
criteria, such as equity and other societal 
benefits.35–37
We included in our scenarios only 
interventions for which effectiveness 
data were available. Due to a lack of 
data we could not examine the manage-
ment of severe malnutrition through 
improved complementary feeding or 
strong community programmes. Mal-
nutrition is a major risk factor for severe 
pneumonia,1 yet no adequate study of 
the preventive effectiveness of such pro-
grammes has been performed.
The links between evidence and 
policy tend to be weak because national 
policies are the outcome of compli-
cated processes among parties with 
different interests.36,37 Impact analysis 
strengthens the selection of optimum 
child packages, and this paper shows 
how policy in this area can be more 
evidence based.  ■
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Résumé
Evaluation comparative des impacts des interventions contre la pneumonie chez l’enfant
Objectif Comparer les rapports coût/efficacité d’interventions 
pour diminuer la mortalité par pneumonie à travers la réduction 
des risques, la vaccination et la prise en charge des cas.
Méthodes Nous avons utilisé des estimations établies par l’OMS 
pour la charge de pneumonies par pays et les coûts des 
interventions afin d’analyser les estimations du risque de pneumonie 
chez les enfants de moins de 5 ans et l’efficacité d’un certain 
nombre d’interventions (prise en charge des cas, vaccinations 
en rapport avec la pneumonie, amélioration de la nutrition et 
réduction de la pollution de l’air intérieur due aux combustibles 
solides ménagers). Nous avons calculé les bénéfices pour la santé 
[années de vie corrigées de l’incapacité (DALY) évitées] et les 
coûts des interventions sur une période de 10 ans pour 40 pays 
totalisant 90 % des décès d’enfants par pneumonie.
Résultats L’utilisation de combustibles fossiles contribue pour 
30 % (intervalle de confiance à 95 % : 18-44) à la charge 
de pneumonie infantile. Le traitement efficace au niveau 
communautaire, la promotion de l’allaitement exclusif, la 
supplémentation en zinc et les vaccinations contre Haemophilus 
influenzae type B (Hib) et Streptocccus pneumoniae par le biais des 
programmes existants ont présenté des rapports coût/efficacité de $ 
int. 10 à $ int. 60 par DALY dans les pays à faible revenu et inférieurs 
à $ int. 120 par DALY dans les pays à revenu moyen. L’utilisation 
de fourneaux à biomasse à faible émission et de combustibles 
plus propres pourrait offrir un rapport coût/efficacité satisfaisant 
dans les régions à faible revenu. Le traitement en établissement 
de soins pourrait également fournir un bon rapport coût/efficacité, 
situé entre $ int. 60 et 120 par DALY. Le rapport coût/efficacité de 
la prise en charge des cas au niveau communautaire dépend du 
coût des visites à domicile.
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Resumen
Evaluación comparativa del impacto de las intervenciones contra la neumonía en la niñez
Objetivo Comparar la costoeficacia de las intervenciones tendentes 
a reducir la mortalidad por neumonía mediante la reducción del 
riesgo, la inmunización y el manejo de casos.
Métodos Partiendo de estimaciones de la carga de neumonía 
por países y del costo de las intervenciones según la OMS, se 
analizaron las estimaciones del riesgo de neumonía entre los 
menores de 5 años y la eficacia de las intervenciones (manejo 
de casos, vacunas relacionadas con la neumonía, mejoras de 
la nutrición y reducción de la contaminación del aire en locales 
cerrados por combustibles sólidos domésticos). Calculamos los 
beneficios para la salud (años de vida ajustados en función de la 
discapacidad -AVAD- evitados) y el costo de las intervenciones 
a lo largo de 10 años para 40 países, abarcando el 90% de las 
defunciones por neumonía en la niñez.
Resultados El uso de combustibles sólidos contribuye en un 30% 
(intervalo de confianza del 90%: 18–44) a la carga de neumonía 
en la niñez. Un tratamiento comunitario eficaz, la promoción de la 
lactancia natural como alimentación exclusiva, la administración 
de suplementos de zinc y la inmunización contra Haemophilus 
influenzae tipo b (Hib) y Streptococcus pneumoniae a través de los 
programas existentes mostraron unas relaciones costo-eficacia 
de 10–60 dólares internacionales (I$) por AVAD en los países de 
ingresos bajos, y de menos de I$ 120 por AVAD en los países 
de ingresos medios. Las estufas de biomasa de baja emisión y 
unos combustibles más limpios pueden ser costoeficaces en las 
regiones de ingresos bajos. La administración de tratamiento 
en servicios de salud es una opción potencialmente costoeficaz, 
pues supone I$ 60–120 por AVAD. La relación costo-eficacia del 
manejo de casos comunitario depende del costo de las visitas 
domiciliarias.
Conclusión La vacunación contra Hib y S. pneumoniae, el manejo 
eficaz de los casos, la promoción de la lactancia natural y la 
administración de suplementos de zinc son medidas costoeficaces 
contra la mortalidad en la niñez. Las intervenciones ambientales 
y nutricionales reducen la neumonía y reportan también otros 
beneficios. La combinación de estas estrategias puede reducir en 
total la mortalidad en la niñez en un 17%.
Conclusion La vaccination contre Hib et S. pneumoniae, la prise 
en charge efficace des cas, la promotion de l’allaitement maternel 
et la supplémentation en zinc sont des interventions présentant 
un bon rapport coût/efficacité dans la réduction de la mortalité 
par pneumonie. Les interventions d’ordre environnemental et 
nutritionnel font régresser la pneumonie et procurent d’autres 
bénéfices. La combinaison de ces stratégies peut permettre une 
réduction globale de la mortalité infantile de 17 %.
صخلم
لافطلأا ىدل يوئرلا باهتللااب ةصاخلا يرثأتل نراقلما مييقتلا
 تايفو  تلادعم  ضفخ  لىإ  ةيمارلا  تلاخدتلا  ةيدودرم  ةنراقم  :فدهلا
 عينمتلاو  راطتخلاا  لماوع  ليلقت  للاخ  نم  لافطلأا  ىدل  يوئرلا  باهتللاا
.تلااحلا يربدتو
 يوئرلا  باهتللاا  نع  مجانلا  ءبعلا  تاريدقت  نوثحابلا  مدختسا  :ةقيرطلا
 ةيلماعلا ةحصلا ةمظنم اهتدبكت يتلا تلاخدتلا فيلاكتو دلب لكب صاخلاو
 ةسماخلا نس نود لافطلأا ىدل يوئرلا باهتللاا راطتخا تاريدقت ةعجارلم
 باهتللااب  ةقلعتلما  تاحاقللاو  تلااحلا  يربدت(  تلاخدتلا  ةءافكو رمعلا  نم
 نع  مجانلاو  لزانلما  لخاد  ءاوهلا  ثولت  ليلقتو  ةيذغتلا  ينسحتو  يوئرلا
 رمعلا تاونسب( ةيحصلا دئاوفلا تبسح دقو .)اهيف بلصلا دوقولا مادختسا
 لىع تلاخدتلا فيلاكتو ،)اهيدافت نكمأ يتلا زجعلا ددم باستحاب ةححصلما
 باهتللااب لافطلأا تايفو نم %90 اهيف ثدحت ًادلب 40 في تاونس 10 ىدم
.يوئرلا
 باهتللاا  ءبع  نم  %30  في  بلصلا  دوقولا  مادختسا  مهاسي  :تادوجولما
 ترهظأ دقو .)44و 18 ينب تحوارت ذإ %90 ةقث ةلصافب( لافطلأا ىدل يوئرلا
 ةعاضرلا لىع راصتقلاا زيزعتو ،عمتجلما لىع ةزكترلما ةلاعفلا ةجلاعلما نم لك
 ةيمدتسلما  حاقلب  عينمتلاو  ،كنزلا  نم  ةيئاذغ  تلامكم ميدقتو  ،يدثلا  نم
 ةيدودرم ترهظأ ،ةئماقلا جمابرلا برع ةيوئرلا تايدقعلاو B طمنلا نم ةيلزنلا
 ةححصلما  رمعلا  تاونس  نم  ةنس  لكل  ًايلود  ًارلاود  60  –  10  تغلب  ةيلاع
 ًارلاود  120  نم  لقأو  ،لخدلا  ةضفخنلما  نادلبلا  في  زجعلا  ددم  باستحاب
 في  زجعلا  ددم  باستحاب  ةححصلما  رمعلا  تاونس  نم  ةنس  لكل  ًايكيرمأ
 نم ةليئض تاثاعبنا جتنت يتلا دقاوملل نوكي دقو .لخدلا ةطسوتلما نادلبلا
 لخدلا ةضفخنلما قطانلما في ةيلاع ةيدودرم فيظنلا دوقوللو ةيويحلا ةلتكلا
 نأ نكيم ثيح ةيدودرلما ةيلاع ةيحصلا قفارلما في ةجلاعلما نوكت نأ نكيمو
 رمعلا  تاونس  نم  ةنس  لكل  ًايلود  ًارلاود  120و  60  ينب  اهتلادعم  حوارـتـت
 عمتجلما في تلااحلا يربدت ةيدودرم دمتعتو .زجعلا ددم باستحاب ةححصلما
.ةيلزنلما تارايزلا فيلاكت لىع
 B  طمنلا  نم  ةيلزنلا  تايمدتسلما  دض  حيقلتلا  نم  ٌّلك  دعي  :جاتنتسلاا
 نم ةيئاذغ تلامكم ميدقتو يدثلا نم ةعاضرلا زيزعتو ،ةيوئرلا تايدقعلاو
 باهتللاا نع ةمجانلا تايفولا تلادعم ضفخل دودرلما ةيلاع تلاخدت كنزلا
 عفانم مدقتو يوئرلا باهتللاا نم ةيوذغتلاو ةيئيبلا تلاخدتلا للقتو .يوئرلا
 تلادعم لمجم ةعمتجم اهقيبطت دنع تايجيتاترسلاا هذه ضفخت دقو ،ىرخأ
.%17 رادقبم لافطلأا تايفو
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